Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Intangibles (2016 - 2025)

Historic Intangibles for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to $22.8 billion.

  • Gsk's Intangibles rose 1666.04% to $22.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $22.8 billion, marking a year-over-year increase of 1666.04%. This contributed to the annual value of $19.8 billion for FY2024, which is 796.82% up from last year.
  • Gsk's Intangibles amounted to $22.8 billion in Q3 2025, which was up 1666.04% from $20.5 billion recorded in Q2 2025.
  • In the past 5 years, Gsk's Intangibles ranged from a high of $41.7 billion in Q3 2021 and a low of $14.3 billion during Q2 2022
  • Its 5-year average for Intangibles is $24.0 billion, with a median of $19.9 billion in 2024.
  • As far as peak fluctuations go, Gsk's Intangibles crashed by 6507.36% in 2022, and later soared by 3572.19% in 2023.
  • Over the past 5 years, Gsk's Intangibles (Quarter) stood at $40.5 billion in 2021, then tumbled by 58.58% to $16.8 billion in 2022, then grew by 9.14% to $18.3 billion in 2023, then rose by 8.64% to $19.9 billion in 2024, then grew by 14.25% to $22.8 billion in 2025.
  • Its Intangibles stands at $22.8 billion for Q3 2025, versus $20.5 billion for Q2 2025 and $20.5 billion for Q1 2025.